Practice Essentials

Best Practice for Newly Diagnosed Myeloma Patients Eligible for Transplant: How Can We Optimize Therapy?
Best Practice for Newly Diagnosed Myeloma Patients Eligible for Transplant: How Can We Optimize Therapy?
CME, CPE
Muhamed Baljevic, MD
Release Date: March 31, 2021
Expiration Date: March 31, 2022

In this activity, Dr. Baljevic discusses patients with newly diagnosed multiple myeloma who are eligible for transplant and reviews recent data from trials evaluating novel multi-drug combinations in the frontline setting. He also identifies the management of treatment-emergent adverse events that are associated with different treatment approaches.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Takeda Oncology.
CE ExpiredView Only, No Credit
 
Overcoming Challenges in Smoldering Multiple Myeloma: Improving Diagnosis and Treatment Selection
Overcoming Challenges in Smoldering Multiple Myeloma: Improving Diagnosis and Treatment Selection
CME, CPE
Noopur Raje, MD
Release Date: January 18, 2021
Expiration Date: January 18, 2022

Smoldering multiple myeloma is an asymptomatic stage that occurs in between MGUS and active multiple myeloma. In this activity, Dr. Noopur Raje provides best practice regarding the diagnosis and management choice for patients with smoldering multiple myeloma. Furthermore, she describes the revised 20/2/20 risk stratification model and the implications on treatment decision making.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Takeda Oncology.
CE ExpiredView Only, No Credit
 
Changing Standards in Transplant-Ineligible Patients Newly Diagnosed with Myeloma
Changing Standards in Transplant-Ineligible Patients Newly Diagnosed with Myeloma
CME, CPE
Saad Z. Usmani, MD, FACP
Release Date: November 30, 2020
Expiration Date: November 30, 2021

The treatment of transplant-ineligible patients with newly diagnosed myeloma remains a clinical challenge, but recent developments in novel therapeutic approaches have been shown to improve outcomes in these patients. In this activity, Dr. Usmani reviews the key clinical data in transplant-ineligible, newly diagnosed myeloma, and provides evidence-based recommendations for choosing individualized treatment regimens.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Takeda Oncology.
CE ExpiredView Only, No Credit
 
Changing Treatment Paradigms in Heavily Pre-Treated RRMM Patients
Changing Treatment Paradigms in Heavily Pre-Treated RRMM Patients
CME, CPE
Sagar Lonial, MD, FACP
Release Date: May 20, 2020
Expiration Date: May 20, 2021

Treating patients with relapsed/refractory multiple myeloma (RRMM) has become more challenging with the introduction of new agents. In this activity, Dr. Lonial discusses the management of RRMM, given the new number of agents available, and which options are the best choice at the different stages of care. He will also review disease-related factors, treatment-related factors, and patient-related factors when considering treatment selection.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation.
CE ExpiredView Only, No Credit
 
Factors to Consider in the Treatment of Early Relapsed/Refractory Multiple Myeloma
Factors to Consider in the Treatment of Early Relapsed/Refractory Multiple Myeloma
CME, CPE
Sikander Ailawadhi, MD
Release Date: February 07, 2020
Expiration Date: February 07, 2021

Managing a newly diagnosed patient with multiple myeloma can present challenges. In this activity, Dr. Ailawadhi covers the key aspects of treatment for patients living with relapsed or refractory multiple myeloma.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation.
CE ExpiredView Only, No Credit